Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-895 + Navtemadlin in R/R FLT3+ AML
NCT04669067Phase 2Active, not recruiting
- Sponsor
- Telios Pharma
- Start
- Mar 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of TL-895 in acute myeloid leukemia (AML), sponsored by Telios Pharma. Started Mar 2021; status: active, not recruiting.
02
Drugs
TL-895
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04669067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669067.